Skip to main content
PMC home page
Heart logoLink to Heart
. 1999 Sep;82(3):325–332. doi: 10.1136/hrt.82.3.325

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment

D Pickin 1, C McCabe 1, L Ramsay 1, N Payne 1, I Haq 1, W Yeo 1, P Jackson 1
PMCID: PMC1729169  PMID: 10455083

Abstract

OBJECTIVES—To estimate the cost effectiveness of statin treatment in preventing coronary heart disease (CHD) and to examine the effect of the CHD risk level targeted and the cost of statins on the cost effectiveness of treatment.
DESIGN—Cohort life table method using data from outcome trials.
MAIN OUTCOME MEASURES—The cost per life year gained for lifelong statin treatment at annual CHD event risks of 4.5% (secondary prevention) and 3.0%, 2.0%, and 1.5% (all primary prevention), with the cost of statins varied from £100 to £800 per year.
RESULTS—The costs per life year gained according to annual CHD event risk were: for 4.5%, £5100; 3.0%, £8200; 2.0%, £10 700; and 1.5%, £12 500. Reducing the cost of statins increases cost effectiveness, and narrows the difference in cost effectiveness across the range of CHD event risks.
CONCLUSIONS—At current prices statin treatment for secondary prevention, and for primary prevention at a CHD event risk 3.0% per year, is as cost effective as many treatments in wide use. Primary prevention at lower CHD event risks (< 3.0% per year) is less cost effective and unlikely to be affordable at current prices and levels of health service funding. As the cost of statins falls, primary prevention at lower risk levels becomes more cost effective. However, the large volume of treatment needed will remain a major problem.


Keywords: coronary artery disease; cost effectiveness; statins; primary prevention; secondary prevention

Full Text

The Full Text of this article is available as a PDF (117.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

Cost per life year gained related to the annual risk of CHD targeted for treatment, assuming lifelong treatment with simvastatin.

Figure 2  .

Figure 2  

Open in a new tab

Marginal cost per life year gained assuming lifelong treatment with a statin, related to the annual cost per person of statin treatment, at CHD event risks of 4.5%, 3.0%, 2.0%, and 1.5% per year.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashraf T., Hay J. W., Pitt B., Wittels E., Crouse J., Davidson M., Furberg C. D., Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15;78(4):409–414. doi: 10.1016/s0002-9149(96)00328-1. [DOI] [PubMed] [Google Scholar]
  2. Briggs A., Sculpher M., Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. doi: 10.1002/hec.4730030206. [DOI] [PubMed] [Google Scholar]
  3. Buxton M. J., Drummond M. F., Van Hout B. A., Prince R. L., Sheldon T. A., Szucs T., Vray M. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997 May-Jun;6(3):217–227. doi: 10.1002/(sici)1099-1050(199705)6:3<217::aid-hec267>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  4. Caro J., Klittich W., McGuire A., Ford I., Norrie J., Pettitt D., McMurray J., Shepherd J. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997 Dec 13;315(7122):1577–1582. doi: 10.1136/bmj.315.7122.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cook R. J., Sackett D. L. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995 Feb 18;310(6977):452–454. doi: 10.1136/bmj.310.6977.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davey Smith G., Egger M. Statistical problems. BMJ. 1994 Apr 16;308(6935):1025–1027. doi: 10.1136/bmj.308.6935.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  8. Evans J. S., Harries C., Dennis I., Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract. 1995 Jan;45(390):15–18. [PMC free article] [PubMed] [Google Scholar]
  9. Goa K. L., Barradell L. B., McTavish D. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. Pharmacoeconomics. 1997 Jan;11(1):89–110. doi: 10.2165/00019053-199711010-00010. [DOI] [PubMed] [Google Scholar]
  10. Grover S. A., Coupal L., Hu X. P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA. 1995 Sep 13;274(10):801–806. [PubMed] [Google Scholar]
  11. Grover S. A., Lowensteyn I., Esrey K. L., Steinert Y., Joseph L., Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 1995 Apr 15;310(6985):975–978. doi: 10.1136/bmj.310.6985.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grundy S. M. More on pravastin and coronary disease. N Engl J Med. 1996 Oct 17;335(16):1239–1240. doi: 10.1056/NEJM199610173351615. [DOI] [PubMed] [Google Scholar]
  13. Grundy S. M. More on pravastin and coronary disease. N Engl J Med. 1996 Oct 17;335(16):1239–1240. doi: 10.1056/NEJM199610173351615. [DOI] [PubMed] [Google Scholar]
  14. Hamilton V. H., Racicot F. E., Zowall H., Coupal L., Grover S. A. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA. 1995 Apr 5;273(13):1032–1038. [PubMed] [Google Scholar]
  15. Haq I. U., Jackson P. R., Yeo W. W., Ramsay L. E. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 1995 Dec 2;346(8988):1467–1471. doi: 10.1016/s0140-6736(95)92477-9. [DOI] [PubMed] [Google Scholar]
  16. Jackson R., Beaglehole R. Evidence-based management of dyslipidaemia. Lancet. 1995 Dec 2;346(8988):1440–1442. doi: 10.1016/s0140-6736(95)92466-3. [DOI] [PubMed] [Google Scholar]
  17. Johannesson M., Jönsson B., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997 Jan 30;336(5):332–336. doi: 10.1056/NEJM199701303360503. [DOI] [PubMed] [Google Scholar]
  18. Jönsson B., Johannesson M., Kjekshus J., Olsson A. G., Pedersen T. R., Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J. 1996 Jul;17(7):1001–1007. doi: 10.1093/oxfordjournals.eurheartj.a014994. [DOI] [PubMed] [Google Scholar]
  19. Martens L. L., Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994 Nov-Dec;16(6):1052–1036. [PubMed] [Google Scholar]
  20. Payne J. N., Milner P. C., Saul C., Bowns I. R., Hannay D. R., Ramsay L. E. Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. BMJ. 1993 Oct 23;307(6911):1027–1030. doi: 10.1136/bmj.307.6911.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Payne N., Saul C. Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality. BMJ. 1997 Jan 25;314(7076):257–261. doi: 10.1136/bmj.314.7076.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pedersen T. R., Kjekshus J., Berg K., Olsson A. G., Wilhelmsen L., Wedel H., Pyörälä K., Miettinen T., Haghfelt T., Faergeman O. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996 May 15;93(10):1796–1802. doi: 10.1161/01.cir.93.10.1796. [DOI] [PubMed] [Google Scholar]
  23. Pharoah P. D., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996 Jun 8;312(7044):1443–1448. doi: 10.1136/bmj.312.7044.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994 Oct;15(10):1300–1331. doi: 10.1093/oxfordjournals.eurheartj.a060388. [DOI] [PubMed] [Google Scholar]
  25. Ramsay L. E., Haq I. U., Jackson P. R., Yeo W. W., Pickin D. M., Payne J. N. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996 Aug 10;348(9024):387–388. doi: 10.1016/s0140-6736(96)05516-x. [DOI] [PubMed] [Google Scholar]
  26. Ramsay L. E., Haq I. U., Jackson P. R., Yeo W. W. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet. 1996 Nov 2;348(9036):1251–1251. doi: 10.1016/s0140-6736(05)65536-5. [DOI] [PubMed] [Google Scholar]
  27. Reckless J. P. The 4S study and its pharmacoeconomic implications. Pharmacoeconomics. 1996 Feb;9(2):101–105. doi: 10.2165/00019053-199609020-00001. [DOI] [PubMed] [Google Scholar]
  28. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  29. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  30. Ul Haq I., Ramsay L. E., Pickin D. M., Yeo W. W., Jackson P. R., Payne J. N. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) 1996 Oct;91(4):399–413. doi: 10.1042/cs0910399. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES